申请人:Merck, Sharp & Dohme, Ltd.
公开号:US05700941A1
公开(公告)日:1997-12-23
A class of substituted 1,2,3,4,5,6,7,8-octahydronaphthyridine derivatives are ligands for dopamine receptor subtypes within the body, in particular the D.sub.4 subtype, and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia or depression.
一类取代的1,2,3,4,5,6,7,8-八氢萘啶衍生物是体内多巴胺受体亚型的配体,特别是D.sub.4亚型,因此在多巴胺系统紊乱的治疗和/或预防中特别有用,特别是在精神分裂症或抑郁症的治疗中。